Changes

As of March 2023 a phase 3 randomized trial is recruiting for patients with superficial bladder cancer. One arm will receive instillations of abnoba mistletoe into their bladder and compared with the chemotherapy mitomycin c.<ref>https://clinicaltrials.gov/ct2/show/NCT02106572</ref>  

As of March 2023 a phase 3 randomized trial is recruiting for patients with superficial bladder cancer. One arm will receive instillations of abnoba mistletoe into their bladder and compared with the chemotherapy mitomycin c.<ref>https://clinicaltrials.gov/ct2/show/NCT02106572</ref>  

A phase 2, single arm study of osteosarcoma patients with fully resected pulmonary metastases will be conducted at [[:en:MD_Anderson_Cancer_Center|University of Texas MD Anderson Cancer Center]]. Participants will receive Iscador® Pini as a prophylactic immunotherapy.<ref>https://beta.clinicaltrials.gov/study/NCT05726383</ref> This trial replicates in part  the 2007 two armed study of post relapse disease free survival in fully resected osteosarcoma. One arm receiving etoposide had an average survival of 7 months (all had recurrence) and the other receiving Iscador Pini had a median survival of 106 months (5 out of 9 without recurrence). <ref><nowiki><ref>{{cite journal | vauthors=((Longhi, A.)), ((Cesari, M.)), ((Serra, M.)), ((Mariani, E.)) | journal=Sarcoma | title=Long-Term Follow-up of a Randomized Study of Oral Etoposide versus </nowiki>''Viscum album'' Fermentatum Pini as Maintenance Therapy in Osteosarcoma Patients in Complete Surgical Remission after Second Relapse | volume=2020 | pages=e8260730 | date=27 April 2020 | url=<nowiki>https://www.hindawi.com/journals/sarcoma/2020/8260730/</nowiki> | doi=10.1155/2020/8260730 | access-date=15 March 2023}}<nowiki></ref></nowiki></ref>

A phase 2, single arm study of osteosarcoma patients with fully resected pulmonary metastases will be conducted at [[:en:MD_Anderson_Cancer_Center|University of Texas MD Anderson Cancer Center]]. Participants will receive Iscador® Pini as a prophylactic immunotherapy.<ref>https://beta.clinicaltrials.gov/study/NCT05726383</ref> This trial replicates in part  the 2007 two armed study of post relapse disease free survival in fully resected osteosarcoma. One arm receiving etoposide had an average survival of 7 months (all had recurrence) and the other receiving Iscador Pini had a median survival of 106 months (5 out of 9 without recurrence).<ref>{{cite journal | vauthors=((Becker, H.)) | journal=Oncology | title=Botany of European Mistletoe (Viscum album L.) | volume=43 | issue=1 | pages=2–7 | date= 1986 | url=https://www.karger.com/Article/FullText/226413 | doi=10.1159/000226413 | access-date=13 March 2023}}</ref>

A Phase 1, dose finding trial is being conducted on Iscador Pini in Israel. <ref>https://beta.clinicaltrials.gov/study/NCT04376931</ref><br />

A Phase 1, dose finding trial is being conducted on Iscador Pini in Israel. <ref>https://beta.clinicaltrials.gov/study/NCT04376931</ref><br />

*{{Cite book| publisher = SteinerBooks, Incorporated| isbn = 978-1-938685-33-0| last1 = Johnson| first1 = Steven| last2 = Winters| first2 = Nasha| last3 = Blanning| first3 = Adam| last4 = Debus| first4 = Marion| last5 = Faust| first5 = Paul| last6 = Hancock| first6 = Mark| last7 = Hinderberger| first7 = Peter| title = Mistletoe and the Emerging Future of Integrative Oncology| date = 2022-02-25}}

*{{Cite book| publisher = SteinerBooks, Incorporated| isbn = 978-1-938685-33-0| last1 = Johnson| first1 = Steven| last2 = Winters| first2 = Nasha| last3 = Blanning| first3 = Adam| last4 = Debus| first4 = Marion| last5 = Faust| first5 = Paul| last6 = Hancock| first6 = Mark| last7 = Hinderberger| first7 = Peter| title = Mistletoe and the Emerging Future of Integrative Oncology| date = 2022-02-25}}

==Weblinks==

==Weblinks==